Bungaro Maristella, Bertaglia Valentina, Audisio Marco, Parlagreco Elena, Pisano Chiara, Cetoretta Valeria, Persano Irene, Jacobs Francesca, Baratelli Chiara, Consito Lorena, Reale Maria Lucia, Tabbò Fabrizio, Bironzo Paolo, Scagliotti Giorgio Vittorio, Novello Silvia
Medical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Explor Target Antitumor Ther. 2021;2(5):481-489. doi: 10.37349/etat.2021.00058. Epub 2021 Oct 31.
Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensure optimal care, especially in frail groups such as cancer patients (pts). This study investigated the efficacy of SARS-CoV-2 pre-procedure screening and whether COVID-19 influenced timely diagnosis and therapy.
Data of oncological procedures of pts with confirmed or suspected cancer diagnosis, treated at Oncology Department or coming from Emergency Department of San Luigi Gonzaga Hospital between June 2020 and March 2021 were retrospectively collected. A nasopharyngeal swab (NPS) was performed in outpatients 24/48 h before procedures. Inpatients were tested by NPS before and after hospitalization.
Two hundred and twenty-one pts were included in this analysis. Median age was 73 years, males were 58%. Eastern Cooperative Oncology Group (ECOG) Performance Status was 0 or 1 in 88% of pts. The most frequent cancer type was lung cancer (57%). Stages IV were 77%. Two hundred and forty-three scheduled procedures were performed with diagnostic (: 142; 58%), therapeutic (: 55; 23%), and palliative (: 46; 19%) intent. One hundred and four and 139 procedures were performed in out- and in-pts, respectively. Of the 234 NPS performed, 10 (4%) were positive. Two pts were infected during hospitalization, 8 in community. Most of them were asymptomatic, while only 2 had mild symptoms. Eight procedures (3%) were postponed, 1 cancelled, while 2 were performed in positive pts. Median time to resolution of the infection was 17 days (11-36). Median delay in the procedures was 25 days (14-55). Five pts started systemic treatment, after a median time of 37.5 days (13-57).
SARS-CoV-2 infection led to the postponement of a small, but not negligible percentage of oncological procedures. However, the low infection rate observed suggests that structured screening for COVID-19 is critical for the best management of scheduled procedures during pandemic.
由于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染在全球迅速传播,意大利迅速成为受影响最严重的国家之一。医疗系统采取了严格的感染控制措施,以确保提供最佳护理,尤其是在癌症患者等脆弱群体中。本研究调查了SARS-CoV-2术前筛查的效果以及2019冠状病毒病(COVID-19)是否影响及时诊断和治疗。
回顾性收集2020年6月至2021年3月期间在圣路易吉·贡扎加医院肿瘤科接受治疗或来自急诊科的确诊或疑似癌症诊断患者的肿瘤治疗数据。门诊患者在手术前24/48小时进行鼻咽拭子(NPS)检测。住院患者在住院前后进行NPS检测。
本分析纳入了221例患者。中位年龄为73岁,男性占58%。88%的患者东部肿瘤协作组(ECOG)体能状态为0或1。最常见的癌症类型是肺癌(57%)。IV期占77%。共进行了243例预定手术,诊断性手术(:142例;58%)、治疗性手术(:55例;23%)和姑息性手术(:46例;19%)。门诊和住院患者分别进行了104例和139例手术。在进行的234次NPS检测中,10例(4%)呈阳性。2例患者在住院期间感染,8例在社区感染。大多数患者无症状,只有2例有轻微症状。8例手术(3%)推迟,1例取消,2例在阳性患者中进行。感染消退的中位时间为17天(11 - 36天)。手术的中位延迟时间为25天(14 - 55天)。5例患者在中位时间37.5天(13 - 57天)后开始全身治疗。
SARS-CoV-2感染导致一小部分但不可忽视的肿瘤手术推迟。然而,观察到的低感染率表明,针对COVID-19的结构化筛查对于大流行期间预定手术的最佳管理至关重要。